Is SLS or CNTA more profitable?

SELLAS Life Sciences Group's return on equity of -47.12% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences Group N/A -47.12% -42.63% Centessa Pharmaceuticals N/A -60.37% -44.17%

Does the media favor MIRM or SLS?

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 4 mentions for SELLAS Life Sciences Group. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat SELLAS Life Sciences Group's score of 0.53 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RYTM or SLS?

In the previous week, Rhythm Pharmaceuticals and Rhythm Pharmaceuticals both had 4 articles in the media. SELLAS Life Sciences Group's average media sentiment score of 0.53 beat Rhythm Pharmaceuticals' score of 0.53 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, COGT or SLS?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A

Is COGT or SLS more profitable?

SELLAS Life Sciences Group's return on equity of -47.12% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% SELLAS Life Sciences Group N/A -47.12% -42.63%

Does the media favor COGT or SLS?

In the previous week, SELLAS Life Sciences Group had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for SELLAS Life Sciences Group and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.54 beat SELLAS Life Sciences Group's score of 0.53 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, SLS or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A Belite Bio N/A N/A -$77.61M -$2.53 N/A

Is SLS or BLTE more profitable?

Belite Bio's return on equity of -13.14% beat SELLAS Life Sciences Group's return on equity. Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences Group N/A -47.12% -42.63% Belite Bio N/A -13.14% -12.88%

Does the media refer more to SLS or BLTE?

In the previous week, Belite Bio had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 5 mentions for Belite Bio and 4 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.53 beat Belite Bio's score of -0.54 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

SELLAS Life Sciences Group (SLS) Competitors

$9.07 +0.54 (+6.33%)

Closing price 04:00 PM Eastern

Extended Trading

$9.12 +0.05 (+0.56%)

As of 07:57 PM Eastern

Compare

SLS vs. CNTA, MIRM, RYTM, COGT, and BLTE

Should you buy SELLAS Life Sciences Group stock or one of its competitors? MarketBeat compares SELLAS Life Sciences Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SELLAS Life Sciences Group include Centessa Pharmaceuticals (CNTA), Mirum Pharmaceuticals (MIRM), Rhythm Pharmaceuticals (RYTM), Cogent Biosciences (COGT), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

How does SELLAS Life Sciences Group compare to Centessa Pharmaceuticals?

SELLAS Life Sciences Group (NASDAQ:SLS) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 4 mentions for SELLAS Life Sciences Group and 3 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat SELLAS Life Sciences Group's score of 0.53 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Centessa Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

SELLAS Life Sciences Group presently has a consensus target price of $10.00, suggesting a potential upside of 10.25%. Centessa Pharmaceuticals has a consensus target price of $41.33, suggesting a potential upside of 2.06%. Given SELLAS Life Sciences Group's higher possible upside, equities research analysts plainly believe SELLAS Life Sciences Group is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

SELLAS Life Sciences Group has higher earnings, but lower revenue than Centessa Pharmaceuticals. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Centessa Pharmaceuticals	$15M	417.77	-$197.53M	-$1.79	N/A

SELLAS Life Sciences Group's return on equity of -47.12% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Summary

SELLAS Life Sciences Group and Centessa Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and SELLAS Life Sciences Group (NASDAQ:SLS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Mirum Pharmaceuticals presently has a consensus price target of $139.80, indicating a potential upside of 25.73%. SELLAS Life Sciences Group has a consensus price target of $10.00, indicating a potential upside of 10.25%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SELLAS Life Sciences Group has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

Mirum Pharmaceuticals has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.01	-$23.36M	-$13.61	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Mirum Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 4 mentions for SELLAS Life Sciences Group. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat SELLAS Life Sciences Group's score of 0.53 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mirum Pharmaceuticals beats SELLAS Life Sciences Group on 12 of the 16 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and SELLAS Life Sciences Group (NASDAQ:SLS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

SELLAS Life Sciences Group has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. SELLAS Life Sciences Group's return on equity of -47.12% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

SELLAS Life Sciences Group has lower revenue, but higher earnings than Rhythm Pharmaceuticals. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	38.35	-$196.54M	-$3.13	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

In the previous week, Rhythm Pharmaceuticals and Rhythm Pharmaceuticals both had 4 articles in the media. SELLAS Life Sciences Group's average media sentiment score of 0.53 beat Rhythm Pharmaceuticals' score of 0.53 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rhythm Pharmaceuticals has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market.

Rhythm Pharmaceuticals currently has a consensus price target of $133.13, indicating a potential upside of 25.36%. SELLAS Life Sciences Group has a consensus price target of $10.00, indicating a potential upside of 10.25%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Rhythm Pharmaceuticals is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

SELLAS Life Sciences Group beats Rhythm Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and SELLAS Life Sciences Group (NASDAQ:SLS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, SELLAS Life Sciences Group had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for SELLAS Life Sciences Group and 2 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.54 beat SELLAS Life Sciences Group's score of 0.53 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences currently has a consensus target price of $43.73, indicating a potential upside of 20.43%. SELLAS Life Sciences Group has a consensus target price of $10.00, indicating a potential upside of 10.25%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cogent Biosciences is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Cogent Biosciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market.

SELLAS Life Sciences Group's return on equity of -47.12% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

Summary

Cogent Biosciences and SELLAS Life Sciences Group tied by winning 7 of the 14 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Belite Bio?

SELLAS Life Sciences Group (NASDAQ:SLS) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Belite Bio's return on equity of -13.14% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Belite Bio	N/A	-13.14%	-12.88%

SELLAS Life Sciences Group currently has a consensus target price of $10.00, suggesting a potential upside of 10.25%. Belite Bio has a consensus target price of $203.00, suggesting a potential upside of 39.91%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts clearly believe Belite Bio is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

SELLAS Life Sciences Group has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market.

Belite Bio is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

In the previous week, Belite Bio had 1 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 5 mentions for Belite Bio and 4 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.53 beat Belite Bio's score of -0.54 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Belite Bio beats SELLAS Life Sciences Group on 7 of the 13 factors compared between the two stocks.

Get SELLAS Life Sciences Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLS vs. The Competition

Export

Metric	SELLAS Life Sciences Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.68B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-39.43	11.07	21.07	22.20
Price / Sales	N/A	334.82	530.36	110.15
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	19.72	8.29	10.79	6.50
Net Income	-$26.86M	$23.85M	$3.56B	$336.88M
7 Day Performance	20.45%	5.21%	1.67%	-0.22%
1 Month Performance	16.58%	2.19%	0.43%	0.77%
1 Year Performance	430.41%	60.99%	32.84%	31.57%

SELLAS Life Sciences Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLS SELLAS Life Sciences Group	0.7591 of 5 stars	$9.07 +6.3%	$10.00 +10.3%	+453.9%	$1.68B	N/A	N/A	10	Options Volume
CNTA Centessa Pharmaceuticals	1.5824 of 5 stars	$39.76 +0.1%	$41.33 +4.0%	+223.3%	$6.14B	$15M	N/A	200
MIRM Mirum Pharmaceuticals	3.9901 of 5 stars	$101.00 +1.7%	$139.80 +38.4%	+114.1%	$6.06B	$521.31M	N/A	140	Positive News
RYTM Rhythm Pharmaceuticals	2.9059 of 5 stars	$89.70 +1.5%	$132.63 +47.9%	+63.6%	$6.06B	$189.76M	N/A	140	High Trading Volume
COGT Cogent Biosciences	2.06 of 5 stars	$33.17 +0.2%	$43.73 +31.8%	+395.7%	$5.66B	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLS) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. CNTA, MIRM, RYTM, COGT, and BLTE

How does SELLAS Life Sciences Group compare to Centessa Pharmaceuticals?

Summary

How does SELLAS Life Sciences Group compare to Mirum Pharmaceuticals?

Summary

How does SELLAS Life Sciences Group compare to Rhythm Pharmaceuticals?

Summary

How does SELLAS Life Sciences Group compare to Cogent Biosciences?

Summary

How does SELLAS Life Sciences Group compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. CNTA, MIRM, RYTM, COGT, and BLTE

How does SELLAS Life Sciences Group compare to Centessa Pharmaceuticals?

Does the media prefer SLS or CNTA?

Which has more volatility and risk, SLS or CNTA?

Do insiders and institutionals believe in SLS or CNTA?

Do analysts recommend SLS or CNTA?

Which has higher earnings and valuation, SLS or CNTA?

Is SLS or CNTA more profitable?

Summary

How does SELLAS Life Sciences Group compare to Mirum Pharmaceuticals?

Do institutionals & insiders believe in MIRM or SLS?

Do analysts rate MIRM or SLS?

Is MIRM or SLS more profitable?

Which has stronger valuation & earnings, MIRM or SLS?

Which has more risk and volatility, MIRM or SLS?

Does the media favor MIRM or SLS?

Summary

How does SELLAS Life Sciences Group compare to Rhythm Pharmaceuticals?

Is RYTM or SLS more profitable?

Which has preferable earnings and valuation, RYTM or SLS?

Does the media refer more to RYTM or SLS?

Do insiders and institutionals have more ownership in RYTM or SLS?

Which has more risk and volatility, RYTM or SLS?

Do analysts prefer RYTM or SLS?

Summary

How does SELLAS Life Sciences Group compare to Cogent Biosciences?

Do insiders & institutionals believe in COGT or SLS?

Does the media favor COGT or SLS?

Do analysts prefer COGT or SLS?

Which has higher earnings and valuation, COGT or SLS?

Which has more risk & volatility, COGT or SLS?

Is COGT or SLS more profitable?

Summary

How does SELLAS Life Sciences Group compare to Belite Bio?

Do insiders and institutionals hold more shares of SLS or BLTE?

Is SLS or BLTE more profitable?

Do analysts prefer SLS or BLTE?

Which has more risk and volatility, SLS or BLTE?

Which has higher valuation and earnings, SLS or BLTE?

Does the media refer more to SLS or BLTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools